Diagnostic and Prognostic Values of Microfibrillar-Associated Protein 5 and Heat Shock Protein 90 Alpha in Patients with HCV-Induced Hepatocellular Carcinoma Undergoing Locoregional Therapy.

Authors

Reem Alaa El-Din Mosbbah, Mohamed Abd El-Maksoud, Salwa M Abo El-Khair, Usama Shiha, Ahmed El-Eraky, Walaa Shabana

Published in

Asian Pacific journal of cancer prevention : APJCP. Volume 27. Issue 8. Pages 2941-2948. Aug 01, 2026. Epub Aug 01, 2026.

Abstract

This study aimed to assess the role of HSP90 alpha and MFAP5 as potential diagnostic and prognostic markers for HCC patients after treatment.
A prospective interventional study included 75 patients of which 50 patients had HCC and 25 were cirrhotic. The control group included 15 age and sex matched healthy subjects. Serum levels of alpha-fetoprotein (AFP), HSP90α and MFAP5 were measured. Patients with HCC received therapeutic interventions (MWA or TACE) and were monitored for one year.
AFP, HSP90α, and MFAP5 levels were significantly higher in HCC patients than cirrhotic patients and controls, and in cirrhotic patients than controls. Patients with tumor diameter more than 5cm, multifocal lesions, and BCLC B staging, higher HSP90α and MFAP5 were significantly more frequent in non-successful group after locoregional therapy compared to successful group. Overall survival in HCC patients was longer when HSP90α was < 243.55 ng/ml (96% and 88% at 6 and 12 months), and when MFAP5 was < 5509.3 pg /ml (96% and 92% at 6 and 12 months).
HSP90α and MFAP5 can be used as diagnostic and prognostic markers for HCC patients after therapy.

PMID:
42663215
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.